Dishman Pharmaceuticals & Chemicals has entered into an agreement with a leading British company Nuscaan for the development & manufacturing of bulk actives for neutraceutical products. According to a release issued by Dishman to the BSE today, Nuscaan is marketing the products in Europe including UK, North America, Australia, New Zealand, South Africa and Japan. The agreement recognises the R&D capabilities of the Dishman group including the newly acquired Synprotech in UK by the company and is an initial step towards a broader co-operation between the two companies, the release said. Dishman also announced the acquisition of the business, together with the technology basket, of C6, a UK group of speciality chemical products for an undisclosed sum.
